YKL-40 as a novel diagnostic biomarker in Toxoplasmosis

被引:5
|
作者
Shahad, Farah Abd AL-Zahra [1 ]
Mohammed, Ahmed A. [1 ]
Jasim, Ghaith Ali [2 ]
机构
[1] Univ Mustansiriyah, Branch Clin Lab Sci, Coll Pharm, Baghdad, Iraq
[2] Univ Mustansiriyah, Branch Pharmacol & Toxicol, Coll Pharm, Baghdad, Iraq
关键词
biomarkers; diagnosis; Toxoplasma gondii; Toxoplasmosis; YKL-40; PREGNANT-WOMEN; GONDII; IMMUNITY; EPIDEMIOLOGY; PATHOGENESIS; IGM;
D O I
10.47750/jptcp.2022.932
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Toxoplasmosis is one of the most globally prevalent zoonotic infection caused by an obligate, intracellular parasite called Toxoplasma gondii. Toxoplasmosis actively triggers an acute immune response and inflammatory reactions, which causes serious pathological changes in various tissues in the human body, and more evidently localizes in different nervous tissues of various body organs. The YKL-40 is a glycoprotein secreted by numerous cell types in different patterns associated with various pathological processes such as inflammatory reactions, tissue remodeling, and fibrosis, and is a disease-specific biomarker of neuroinflammation. Therefore, this study aimed to determine whether the YKL-40 is markedly increased in toxoplasmosis or not and whether its level is different between the acute and chronic phases of the infection to determine if it can be used as a clinically useful biomarker in the diagnosis, and determination of disease severity and follow-up of toxoplasmosis. Accordingly, a total of 80 serum samples were collected from previously diagnosed female patients of different ages with toxoplasmosis. In addition, serum samples of 10 healthy females were used as the control. Patients were first divided into two groups (30 patients with acute infection, and 50 patients with chronic infection) depending on the results of detection of specific anti-Toxoplasma IgM and IgG by enzyme linked immunosorbent assay (ELISA). The level of YKL-40 was then measured in the patients' serum by ELISA. The statistical analysis of data clearly disclosed very highly significant differences (P < 0.001) between the level of YKL-40 in the acute infection group and healthy controls, chronic infection group and healthy controls, and between the groups with acute and chronic infections. These findings led to conclude that YKL-40 classify as a unique and sophisticated biomarker in the diagnosis of toxoplasmosis where it can vitally be used to detect the stage of the disease, whether acute or chronic, besides its ability to detect the infection.
引用
收藏
页码:E61 / E70
页数:10
相关论文
共 50 条
  • [21] YKL-40 as a biomarker in various inflammatory diseases: A review
    Blazevic, Nina
    Rogic, Dunja
    Pelajic, Stipe
    Miler, Marijana
    Glavcic, Goran
    Ratkajec, Valentina
    Vrkljan, Nikolina
    Bakula, Dejan
    Hrabar, Davor
    Pavic, Tajana
    BIOCHEMIA MEDICA, 2024, 34 (01)
  • [22] Serum YKL-40 as a potential biomarker of inflammation in psoriasis
    Baran, Anna
    Mysliwiec, Hanna
    Szterling-Jaworowska, Malgorzata
    Kiluk, Paulina
    Swiderska, Magdalena
    Flisiak, Iwona
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 (01) : 19 - 23
  • [23] YKL-40 - an emerging biomarker in cardiovascular disease and diabetes
    Camilla N Rathcke
    Henrik Vestergaard
    Cardiovascular Diabetology, 8
  • [24] YKL-40 IDENTIFIED BY PROTEOMIC ANALYSIS AS A BIOMARKER OF SEPSIS
    Hattori, Noriyuki
    Oda, Shigeto
    Sadahiro, Tomohito
    Nakamura, Masataka
    Abe, Ryuzo
    Shinozaki, Koichiro
    Nomura, Fumio
    Tomonaga, Takeshi
    Matsushita, Kazuyuki
    Kodera, Yoshio
    Sogawa, Kazuyuki
    Satoh, Mamoru
    Hirasawa, Hiroyuki
    SHOCK, 2009, 32 (04): : 393 - 400
  • [25] Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state
    Bjorn, Mads Emil
    Andersen, Christen Lykkegaard
    Jensen, Morten Krogh
    Hasselbalch, Hans C.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 93 (03) : 224 - 228
  • [26] Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases
    Baldacci, Filippo
    Lista, Simone
    Cavedo, Enrica
    Bonuccelli, Ubaldo
    Hampel, Harald
    EXPERT REVIEW OF PROTEOMICS, 2017, 14 (04) : 285 - 299
  • [27] Can YKL-40 be an Inflammatory Biomarker in Vitamin D Deficiency?
    Can, Ummugulsum
    Uysal, Saliha
    Ugur, Ayse Ruveyda
    Toker, Aysun
    Aslan, Uysaler
    Hidayetoglu, Bahauddin Taha
    INTERNATIONAL JOURNAL FOR VITAMIN AND NUTRITION RESEARCH, 2019, 89 (5-6) : 309 - 313
  • [29] The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development
    Baldacci, Filippo
    Lista, Simone
    Palermo, Giovanni
    Giorgi, Filippo Sean
    Vergallo, Andrea
    Hampel, Harald
    EXPERT REVIEW OF PROTEOMICS, 2019, 16 (07) : 593 - 600
  • [30] YKL-40 as a new biomarker of disease activity in Takayasu arteritis
    Sun, Ying
    Kong, Xiufang
    Wu, Sifan
    Ma, Lili
    Yan, Yan
    Lv, Peng
    Jiang, Lindi
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2019, 293 : 231 - 237